Literature DB >> 11341862

Intermittent Claudication.

Alan T. Hirsch1, Laura M Reich.   

Abstract

Intermittent claudication is the most common symptom in patients with peripheral arterial disease (PAD). As such, it is mandatory for clinicians to treat both the PAD-specific symptoms (to decrease functional impairment and thereby improve quality- of-life, as well as to decrease rates of amputation) and the underlying systemic atherosclerosis (and thereby reduce cardiovascular ischemic events, especially myocardial infarction and stroke). Most patients with claudication can successfully decrease their exertional limb symptoms via a combination of exercise (preferably supervised) and pharmacotherapeutic interventions (eg, cilostazol). Endovascular revascularization currently serves as an effective therapy for patients with high-grade stenoses of the proximal limb arterial segments, (eg, the distal aorta, common iliac artery, or external iliac artery, and occasionally the proximal common femoral artery). Surgical revascularization usually is reserved for patients who present with severe aortoiliac disease in whom long-term patency is likely to be achieved (eg, aortobifemoral or femoral-femoral bypass) and who have a low cardiovascular perioperative ischemic risk. Patients who undergo successful revascularization also are likely to benefit from exercise rehabilitation programs. All patients with PAD, of any severity, must successfully normalize atherosclerosis risk factors and use antiplatelet therapies. Such interventions include complete smoking cessation, glycemic control, normalization of blood pressure (less than 130/90 mm Hg), and lowering of low-density lipoprotein (LDL) cholesterol to less than 100 mg/dL. Antiplatelet agents (eg, clopidogrel, aspirin) should be prescribed to decrease rates of cardiovascular ischemic events in all patients with PAD, unless otherwise contraindicated.

Entities:  

Year:  2001        PMID: 11341862     DOI: 10.1007/s11936-001-0035-4

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  45 in total

Review 1.  Therapeutic angiogenesis: time for the next phase.

Authors:  G A Pantely; J M Porter
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

Review 2.  Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review.

Authors:  J I Weitz; J Byrne; G P Clagett; M E Farkouh; J M Porter; D L Sackett; D E Strandness; L M Taylor
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

3.  Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Z J Zheng; A R Sharrett; L E Chambless; W D Rosamond; F J Nieto; D S Sheps; A Dobs; G W Evans; G Heiss
Journal:  Atherosclerosis       Date:  1997-05       Impact factor: 5.162

4.  Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group.

Authors:  M Lièvre; S Morand; B Besse; J N Fiessinger; J P Boissel
Journal:  Circulation       Date:  2000-07-25       Impact factor: 29.690

5.  Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985.

Authors:  H A Cameron; P C Waller; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

6.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

7.  The measured effect of stopping smoking on intermittent claudication.

Authors:  C R Quick; L T Cotton
Journal:  Br J Surg       Date:  1982-06       Impact factor: 6.939

8.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

9.  Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.

Authors:  M B Elam; J Heckman; J R Crouse; D B Hunninghake; J A Herd; M Davidson; I L Gordon; E B Bortey; W P Forbes
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-12       Impact factor: 8.311

10.  Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis.

Authors:  A W Gardner; E T Poehlman
Journal:  JAMA       Date:  1995-09-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.